Psilocybin Therapy

Kaya Holdings Advocates For Psilocybin As FDA Rejects MDMA For PTSD Treatment
Utah Hospitals Will Soon Provide Psilocybin And MDMA Therapy For Mental Health Conditions
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Utah Hospitals Will Soon Provide Psilocybin And MDMA Therapy For Mental Health Conditions
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Washington Doctor Vs. DEA For Lawful Use Of Psilocybin To Treat Terminally Ill Patients
Canadian At-Home Microdose Psilocybin Clinical Trial Finalized, Here Are The Details

Psilocybin Therapy Recent News

Canadian Psychedelics Company Launches Take-Home Psilocybin Trial For Some 300 Participants
Apex Labs Ltd., an Iter Investment’s portfolio biopharma company developing psilocybin therapeutics, has been granted approval by Health Canada to begin its large take-home psilocybin clinical trial. 
Virginia Psychedelics: Legalizing Medical Use Of Psilocybin Gets A Thumbs Down
After a positive start of Virginia's 2023 state congressional session, one of the two projects seeking to legalize psychedelics in Virginia received a negative vote from a key House panel on Wednesday, January 18.</
2023 Could Be Make Or Break For Psychedelics In Missouri, This GOP Lawmaker Is Pushing For Change
Missouri Rep. Tony Lovasco (R) recently laid out his plans to file a psychedelics bill providing therapeutic access to psilocybin for those suffering from serious mental health conditions, reported Marijuana Moment.
These Are The 11 Biggest Psychedelics News And Trends You May Have Missed Last Year
What a year for psychedelics!
Oregon's Final Rules For Psilocybin Services Are Ready, Learn What To Expect
Following the November midterm results on local opt-outs, the Oregon Health Authority (OHA) announc
First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval
The partnership leading the way on psilocybin therapy for Fragile X Syndrome (FXS), the major genetic cause of Autism Spectrum Disorder (ASD), has received approval from Health Canada in the form of a No Objection letter and is set to proceed with the first-ever Phase 2a clinical trial on the magic mushrooms therapy for this condition.
Canada: Fed Guidelines For Psychedelic Therapy, Quebec Treatment Costs, Access And Magic Mushrooms Dispensaries
The agency regulating all things related to psychedelic-assisted therapy (PAT), Health Canada released a notice to stakeholders on risk-management measures for clinical trials, a seemingly supporting move towards future government-supported access
Potential Road To At-Home Psychedelics Use Permits: Low Dosing's Positive Outcomes In Phase 1 Trial
Canadian drug development company Diamond Therapeutics Inc. announced it has successfully completed its Phase 1 clinical study on low-dose psilocybin and shared the trial’s most relevant results. 
Magic Mushrooms Tested For Treating Type II Bipolar Disorder, Check Out Results So Far
Mental health care company COMPASS Pathways plc (NASDAQ: CMPS) has announced positive data demonstrating the potential of its proprietary synthetic psilocybin compound COMP360 in treating depression within Type II bipolar disorder.
DEA's Consistent Denial Of Psilocybin Access For Terminally Ill Being Challenged Again
The ongoing battle led by palliative care specialist Dr. Sunil Aggarwal to pressure the DEA to allow end-of-life treatments for patients seeking to use psychedelics introduced another chapter. 
In Oregon You Can Get Trained To Be A Licensed Psilocybin Therapy Provider
Educational platform training and certifying psychedelic therapists Fluence has been selected by Oregon’s Higher Education Coordinating Commission (HECC) and the Oregon Health Authority (OHA) to be a state-licensed provider of training for licensed facilitators to provide psilocybin services under Measure 109.
Cannabis & Psychedelics As Effective Adjunct Medicine To Breast Cancer Therapy? Studies Say Yes
A recent study published by life sciences company Grace Health & Wellness aims to raise awareness on the possibility of using medical cannabis and psychedelics to propel traditional pharmaceuticals.
Why Magic Mushrooms Are Emerging As Major Part Of Public Discourse: What Science Is Saying
(Part three of a four-part series) Despite ongoing legal setbacks, psychedelics research has reemerged and it is proving that psilocybin reduces brain connections within the usual networks while amplifying links between less connected areas. 
Why Magic Mushrooms Are Emerging As Major Part Of Public Discourse: The Legal Situation
(Part one of a four-part series) In recent years, evidence supporting the use of psychedelics for the treatment of unmet mental health disorders such as PTSD, depression, addictions and anxiety has done nothing but grow.
Major Psychedelics Firm Is Studying Magic Mushrooms To Treat Meth Addiction
Life sciences company Revive Therapeutics Ltd. (OTCQB: RVVTF) is advancing its first Phase I/II clinical trial of oral psilocybin for methamphetamine use disorder treatment while also developing an oral psilocybin thin film strip product.
Mindset Pharma Meets With UK Regulator: Is A Phase 1 Trial Getting Close?
Biotech drug discovery firm Mindset Pharma Inc.
Psychedelics Companies Are Teaming Up To Offer Access Veterans
Two psychedelics companies have announced they’ll be collaborating to offer ketamine infusions in the US and psilocybin clinical retreats internationally with a special focus on  access needs for veterans. 
Cathie Wood's Psychedelics Fund ARK Analyzes The Sector's Present & Future And Likes What It Sees
Cathie Wood’s ARK Genomic Revolution EFT has been making big investments in the psychedelics sector since February 2022, most notably in A
Study Finds Psilocybin Anti-Depression Effects Last At Least One Year
This article was originally published on Psychedelic Spotlight and appears here with permission.
The Case For Psilocybin Therapy And Depression
This article was originally published on The Bluntness and appears here with permission. Depression is one of the most widespread and difficult to treat mental illnesses on the planet. 
ATAI Life Sciences Announces New Program To Discover Next-Generation Mental Health Treatments
atai Life Sciences (NASDAQ: ATAI) on Thursday announced Invyxis, a new program to accelerate the company’s portfolio of compounds.
Psilocybin Therapy Combined With SSRI Antidepressants Is Possible, COMPASS Study Confirms
Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ: CMPS) announced Monday it had achieved positive results from its exploratory study of COMP360 psilocybin therapy in conjunction with SSRI use.
Peter Thiel-Backed Psychedelic Start-Up, ATAI Life Sciences, Increases Stake In Compass Pathways
Biopharmaceutical conglomerate ATAI Life Sciences (NASDAQ: ATAI), a Peter Thiel-backed psychedelic startup that currently has 10 psychedelic programs in the works, has upped its stake in Compass Pat

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved